Fig. 5

DRα1-mMOG-35-55 treatment increases the frequency of CD11b⁺CD206⁺ M2 macrophages in spinal cords of mice with EAE. a Frequency of CD206⁺ on CD11b⁺CD45^hi cells from spinal cords of DRα1-mMOG-35-55-treated (n = 6) vs. vehicle-treated (n = 6) C57BL/6 male WT mice with EAE. b Frequency of CD206⁺ on CD11b⁺CD45^hi cells from spleens of DRα1-mMOG-35-55-treated (n = 6) or vehicle-treated (n = 6) C57BL/6 male WT mice with EAE. c Splenocytes from C57BL/6 male WT mice (n = 4) with EAE (day 15 post-immunization) were treated with 10 ng/ml LPS, 100 ng/ml recombinant MIF, and 25 μg/ml DRα1-mMOG-35-55 for 24 h. Frequency of CD206⁺ on CD11b⁺F4/80⁺ cells was evaluated by flow cytometry. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. a, b Student’s t test. c One-way ANOVA with Tukey post-test